This has been demonstrated in preclinical studies in NSCLC cell lines, with Akt activation attributed to loss of PTEN, EGFR or PIK3CA mutation, or HER2 amplification.50 This evidence concerns the gene AKT1 and non-small cell lung carcinoma.